EFFECT OF FARGALS-CONTAININH SUPERSORBICID IN THE COMPLEX TREATMENT ON MAXILLO - FACIAH OSTEOMIELIT
DOI:
https://doi.org/10.55640/Keywords:
maxillofacial region, osteomyelitis, immunology, necrosis, microflora.Abstract
For complex treatment of 90 patients osteomielit for the first time we have used drug FarGALS developed by specialists of research-manufactoring. Clinico-laboratory and bacteriological evaluations of their effi cacy showed that during use of these preparations FarGALS in the complex treatment of abscess was noted more quick liquidation of local and general signs of inflammation, acceleration of wound cleaning from necrotic mass that led to intensifica tion of wound healing by secondary intention.
Downloads
References
1.Klimko N., Khostelidi S., Shadrivova O., Volkova A., Popova M., Uspenskaya O., et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol. 2019;57(Suppl. 2):S138-S144. DOI: 10.1093/mmy/myy116
2.Klimko N.N., Khostelidi S.N., Shadrivova O.V., Bogomolova T.S., Avdeenko Y.L., Volkova A.G., et al. Mucormycosis in oncohematology patients (results of the prospective study). Oncohematology. 2017;12(2):14-22. Russian. (Климко Н.Н., Хостелиди С.Н., Шадривова О.В., Богомолова Т.С., Авдеенко Ю.Л., Волкова А.Г. и соавт. Инвазивный мукормикоз у онкогематологических больных (результаты проспективного исследования). Онкогематология. 2017;12(2):14-22.) DOI: 10.17650/1818-8346-2017-12-2-14-22
3.Rudramurthy S.M., Hoenigl M., Meis J.F., Cornely O.A., Muthu V., Gangneux J.P., et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries. Mycoses. 2021;64(9):1028-1037. DOI: 10.1111/myc.13335
4.Selarka L., Sharma S., Saini D., Sharma S., Batra A., Waghmare V.T., et al. Mucormycosis and COVID-19: an epidemic within a pandemic in India. Mycoses. 2021;64(10):1253-1260. DOI: 10.1111/myc.13353
5.Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. DOI: 10.1016/j.dsx.2021.05.019
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India